These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
238 related articles for article (PubMed ID: 36202311)
21. Advances in the Diagnosis and Treatment of a Driving Target: RET Rearrangements in non-Small-Cell Lung Cancer (NSCLC) Especially in China. Li T; Yang WY; Liu TT; Li Y; Liu L; Zheng X; Zhao L; Zhang F; Hu Y Technol Cancer Res Treat; 2023; 22():15330338221148802. PubMed ID: 36628459 [TBL] [Abstract][Full Text] [Related]
22. Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial. Subbiah V; Wolf J; Konda B; Kang H; Spira A; Weiss J; Takeda M; Ohe Y; Khan S; Ohashi K; Soldatenkova V; Szymczak S; Sullivan L; Wright J; Drilon A Lancet Oncol; 2022 Oct; 23(10):1261-1273. PubMed ID: 36108661 [TBL] [Abstract][Full Text] [Related]
23. Pralsetinib: A Review in Advanced RET Fusion-Positive NSCLC. Syed YY Drugs; 2022 May; 82(7):811-816. PubMed ID: 35587858 [TBL] [Abstract][Full Text] [Related]
24. Selpercatinib: A Review in Advanced RET Fusion-Positive NSCLC. Nie T; Syed YY Target Oncol; 2023 Jan; 18(1):169-176. PubMed ID: 36422787 [TBL] [Abstract][Full Text] [Related]
25. Association Between RET Fusions and Efficacy of Pemetrexed-based Chemotherapy for Patients With Advanced NSCLC in China: A Multicenter Retrospective Study. Shen T; Pu X; Wang L; Yu Z; Li J; Zhang Y; Liang X; Chen H; Xu C; Song Z; Wang W Clin Lung Cancer; 2020 Sep; 21(5):e349-e354. PubMed ID: 32143967 [TBL] [Abstract][Full Text] [Related]
26. Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion-Positive Lung Cancer by Combining Selpercatinib with Crizotinib. Rosen EY; Johnson ML; Clifford SE; Somwar R; Kherani JF; Son J; Bertram AA; Davare MA; Gladstone E; Ivanova EV; Henry DN; Kelley EM; Lin M; Milan MSD; Nair BC; Olek EA; Scanlon JE; Vojnic M; Ebata K; Hechtman JF; Li BT; Sholl LM; Taylor BS; Ladanyi M; Jänne PA; Rothenberg SM; Drilon A; Oxnard GR Clin Cancer Res; 2021 Jan; 27(1):34-42. PubMed ID: 33082208 [TBL] [Abstract][Full Text] [Related]
28. LIBRETTO-432, a phase III study of adjuvant selpercatinib or placebo in stage IB-IIIA Tsuboi M; Goldman JW; Wu YL; Johnson ML; Paz-Ares L; Yang JC; Besse B; Su W; Chao BH; Drilon A Future Oncol; 2022 Sep; 18(28):3133-3141. PubMed ID: 35950566 [TBL] [Abstract][Full Text] [Related]
29. Precision Targeted Therapy with BLU-667 for Subbiah V; Gainor JF; Rahal R; Brubaker JD; Kim JL; Maynard M; Hu W; Cao Q; Sheets MP; Wilson D; Wilson KJ; DiPietro L; Fleming P; Palmer M; Hu MI; Wirth L; Brose MS; Ou SI; Taylor M; Garralda E; Miller S; Wolf B; Lengauer C; Guzi T; Evans EK Cancer Discov; 2018 Jul; 8(7):836-849. PubMed ID: 29657135 [TBL] [Abstract][Full Text] [Related]
30. Treatment of Advanced Non-Small Cell Lung Cancer with RET Fusions: Reality and Hopes. Rocco D; Sapio L; Della Gravara L; Naviglio S; Gridelli C Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768754 [TBL] [Abstract][Full Text] [Related]
31. An updated patent review of rearranged during transfection (RET) kinase inhibitors (2016-present). Acharya B; Frett B Expert Opin Ther Pat; 2022 Oct; 32(10):1067-1077. PubMed ID: 36198171 [TBL] [Abstract][Full Text] [Related]
32. Targeting RET alterations in cancer: Recent progress and future directions. Shabbir A; Kojadinovic A; Shafiq T; Mundi PS Crit Rev Oncol Hematol; 2023 Jan; 181():103882. PubMed ID: 36481304 [TBL] [Abstract][Full Text] [Related]
33. RET-rearranged non-small-cell lung carcinoma: a clinicopathological and molecular analysis. Tsuta K; Kohno T; Yoshida A; Shimada Y; Asamura H; Furuta K; Kushima R Br J Cancer; 2014 Mar; 110(6):1571-8. PubMed ID: 24504365 [TBL] [Abstract][Full Text] [Related]
34. Durable response to low-dose pralsetinib in a renal insufficient patient with NSCLC harboring concurrent CCDC6-RET, LINCO1264-RET, and SEMA5A-RET fusions: A case report. Gu L; Ji W; Xu Y; Han Y; Jian H Medicine (Baltimore); 2022 Nov; 101(47):e31480. PubMed ID: 36451418 [TBL] [Abstract][Full Text] [Related]
35. Emergence of RET rearrangement co-existing with activated EGFR mutation in EGFR-mutated NSCLC patients who had progressed on first- or second-generation EGFR TKI. Klempner SJ; Bazhenova LA; Braiteh FS; Nikolinakos PG; Gowen K; Cervantes CM; Chmielecki J; Greenbowe JR; Ross JS; Stephens PJ; Miller VA; Ali SM; Ou SH Lung Cancer; 2015 Sep; 89(3):357-9. PubMed ID: 26187428 [TBL] [Abstract][Full Text] [Related]
36. Pralsetinib for RET Fusion-Positive Advanced Non-small-Cell Lung Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Al Khayat MNMT; Armstrong N; Howick J; O'Meara S; Posadzki P; Ryder S; Ahmadu C; Konings SRA; Postma MJ; Duffy S; Wolff RF; van Asselt ADI Pharmacoeconomics; 2023 Apr; 41(4):353-361. PubMed ID: 36757608 [TBL] [Abstract][Full Text] [Related]
37. Pralsetinib treatment for multiple Cao X; Liu X; Wang S; Liu Z; Ren X; Sun D; Deng L J Int Med Res; 2022 Jun; 50(6):3000605221105368. PubMed ID: 35751411 [TBL] [Abstract][Full Text] [Related]
38. Pralsetinib: First Approval. Markham A Drugs; 2020 Nov; 80(17):1865-1870. PubMed ID: 33136236 [TBL] [Abstract][Full Text] [Related]
39. Novel targets in non-small cell lung cancer: ROS1 and RET fusions. Gainor JF; Shaw AT Oncologist; 2013; 18(7):865-75. PubMed ID: 23814043 [TBL] [Abstract][Full Text] [Related]
40. Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry. Gautschi O; Milia J; Filleron T; Wolf J; Carbone DP; Owen D; Camidge R; Narayanan V; Doebele RC; Besse B; Remon-Masip J; Janne PA; Awad MM; Peled N; Byoung CC; Karp DD; Van Den Heuvel M; Wakelee HA; Neal JW; Mok TSK; Yang JCH; Ou SI; Pall G; Froesch P; Zalcman G; Gandara DR; Riess JW; Velcheti V; Zeidler K; Diebold J; Früh M; Michels S; Monnet I; Popat S; Rosell R; Karachaliou N; Rothschild SI; Shih JY; Warth A; Muley T; Cabillic F; Mazières J; Drilon A J Clin Oncol; 2017 May; 35(13):1403-1410. PubMed ID: 28447912 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]